Allucent has partnered with eCOA technology provider Thread to launch Allucent Patient Direct Trials, a decentralised clinical trial (DCT) offering that is focused on small and mid-sized biotech firms.
The launch will provide these companies with access to the latest technologies, regulatory expertise, and operational experience.
Allucent improved its patient-centric approaches and guidance for optimising clinical protocols after the Covid-19 pandemic.
Leveraging this experience, the offering will address the needs of the biotech companies in designing and overseeing customised DCT approaches.
The partnership will also help Allucent’s regulatory and product development consultant team to guide sponsors in determining effective digital strategies for remote engagement and data collection for their studies.
Allucent chairman and CEO Mark Goldberg said: “With this launch, we’re helping our clients harness new insights and technologies to be more patient-centric and realise the potential and efficiencies of decentralised approaches to clinical research.”
DCTs can make patient participation more accessible and manageable.
They can also accelerate enrolment, help retain subjects, and increase the overall participant pool diversity to make the trial results more representative for real-world effectiveness.
In March this year, United BioSource and Threadlaunched the next-generation, post-approval research model, SitePlus.
The new research model provides nationwide, direct-to-patient recruitment strategies and enables inclusive, diverse patient population enrolment.
Decentralised Clinical Trial coverage in Clinical Trials Arena is supported by Huma.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
